Great Point Partners
Great Point Partners is a Greenwich, Connecticut-based private equity investment firm founded in 2003 that specializes in healthcare. It targets investments across the healthcare sector, including the biopharmaceutical supply chain, healthcare IT-enabled services, healthcare services, and medical device contract manufacturing, with a geographic focus on the United States, Canada, and Western Europe. The firm pursues a range of strategies, including special situations, buyouts, and growth equity, and supports its portfolio companies through an executive advisory framework that includes a CEO Advisory Board and a Medical Advisory Board. Through multiple funds, the firm continues to invest in healthcare companies with varying deal sizes and EBITDA profiles across its target regions. Great Point Partners operates as an investment partner for management teams seeking growth and operational improvements in the healthcare landscape.
https://crunchbase.com/organization/***
https://linkedin.com/company/***
Past deals in Connecticut
Arvinas
Post in 2023
Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in the discovery, development, and commercialization of innovative therapies aimed at degrading disease-causing proteins. The company's lead product candidates include ARV-110, a proteolysis targeting chimera (PROTAC) currently in phase I clinical trials for metastatic castration-resistant prostate cancer, and ARV-471, which targets the estrogen receptor for patients with metastatic ER-positive/HER2-negative breast cancer. In addition to these, Arvinas is developing various other PROTACs aimed at degrading clinically relevant androgen receptor mutations and treatments for neurodegenerative diseases, including tauopathies. The company has established collaborations with prominent pharmaceutical firms such as Pfizer Inc., Genentech, and Bayer AG, enhancing its research capabilities and reach within the biopharmaceutical landscape. Founded in 2015, Arvinas aims to improve patient outcomes by eliminating harmful proteins from the body through its proprietary technology.
Biodel
Post in 2011
Biodel Inc. is a development-stage biopharmaceutical company based in Danbury, Connecticut, focused on creating and commercializing treatments for diabetes. The company employs its proprietary formulation technologies to enhance existing drugs, with its lead product candidate being Linjeta, a rapid-acting mealtime insulin designed for patients with Type I and Type II diabetes. In addition to Linjeta, Biodel is working on earlier-stage product candidates, including advanced rapid-acting mealtime insulins, a sublingual tablet formulation of insulin known as VIAtab, a range of basal insulins, and a glucagon formulation. Through its innovative approach, Biodel aims to improve the management of endocrine disorders, particularly diabetes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.